196 related articles for article (PubMed ID: 15663330)
1. Technology evaluation: Kahalalide F, PharmaMar.
Hamann MT
Curr Opin Mol Ther; 2004 Dec; 6(6):657-65. PubMed ID: 15663330
[TBL] [Abstract][Full Text] [Related]
2. Technology evaluation: cantuzumab mertansine, ImmunoGen.
Smith SV
Curr Opin Mol Ther; 2004 Dec; 6(6):666-74. PubMed ID: 15663331
[TBL] [Abstract][Full Text] [Related]
3. Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents.
Cruz LJ; Luque-Ortega JR; Rivas L; Albericio F
Mol Pharm; 2009; 6(3):813-24. PubMed ID: 19317431
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship of kahalalide F synthetic analogues.
Jiménez JC; López-Macià A; Gracia C; Varón S; Carrascal M; Caba JM; Royo M; Francesch AM; Cuevas C; Giralt E; Albericio F
J Med Chem; 2008 Aug; 51(16):4920-31. PubMed ID: 18672864
[TBL] [Abstract][Full Text] [Related]
5. CYC-202 Cyclacel.
Guzi T
Curr Opin Investig Drugs; 2004 Dec; 5(12):1311-8. PubMed ID: 15648953
[TBL] [Abstract][Full Text] [Related]
6. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
7. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
8. CC-5013 (Celgene).
Mitsiades CS; Mitsiades N
Curr Opin Investig Drugs; 2004 Jun; 5(6):635-47. PubMed ID: 15242253
[TBL] [Abstract][Full Text] [Related]
9. Su-11248 Sugen.
Sakamoto KM
Curr Opin Investig Drugs; 2004 Dec; 5(12):1329-39. PubMed ID: 15648955
[TBL] [Abstract][Full Text] [Related]
10. BMS-247550 Bristol-Myers Squibb/GBF.
Lin N; Brakora K; Seiden M
Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.
Salazar R; Cortés-Funes H; Casado E; Pardo B; López-Martín A; Cuadra C; Tabernero J; Coronado C; García M; Soto Matos-Pita A; Miguel-Lillo B; Cullell-Young M; Iglesias Dios JL; Paz-Ares L
Cancer Chemother Pharmacol; 2013 Jul; 72(1):75-83. PubMed ID: 23645288
[TBL] [Abstract][Full Text] [Related]
12. Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
Ashour M; Edrada R; Ebel R; Wray V; Wätjen W; Padmakumar K; Müller WE; Lin WH; Proksch P
J Nat Prod; 2006 Nov; 69(11):1547-53. PubMed ID: 17125219
[TBL] [Abstract][Full Text] [Related]
13. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
14. In vitro and in vivo evaluation of select kahalalide F analogs with antitumor and antifungal activities.
Shilabin AG; Hamann MT
Bioorg Med Chem; 2011 Nov; 19(22):6628-32. PubMed ID: 21839640
[TBL] [Abstract][Full Text] [Related]
15. 27th Annual JPMorgan Healthcare Conference--Antisoma and Keryx Biopharmaceuticals.
Croasdell G; Gale S
IDrugs; 2009 Mar; 12(3):152-4. PubMed ID: 19333892
[No Abstract] [Full Text] [Related]
16. Learning from exceptional drug responders.
Mullard A
Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
[No Abstract] [Full Text] [Related]
17. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
Croasdell G; Gale S
IDrugs; 2009 Mar; 12(3):149-51. PubMed ID: 19333891
[No Abstract] [Full Text] [Related]
18. OSI-461 (OSI).
Galmarini CM
Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
[TBL] [Abstract][Full Text] [Related]
19. Marine Depsipeptides as Promising Pharmacotherapeutic Agents.
Rangel M; de Santana CJ; Pinheiro A; Dos Anjos L; Barth T; Pires OR; Fontes W; Castro MS
Curr Protein Pept Sci; 2017; 18(1):72-91. PubMed ID: 27226199
[TBL] [Abstract][Full Text] [Related]
20. AE-941 (AEterna).
Dredge K
Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
